Cardioprotective medication use after renal transplantation

Clinical Transplantation

Volumn 24, Issue 6, 2010, Pages

  Dawson, Kyle L ^a   Patel, Samir J ^a   Putney, David ^a   Suki, Wadi N ^b   Osama Gaber, A ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b Kidney Institute   (United States)

Author keywords

Cardiovascular disease; Drug therapy; Kidney transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

ARTICLE; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 78649856145     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01297.x     Document Type: Article

References (20)

1. U.S. Renal Data System, USRDS 2007. Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007.
2. Ojo AO, Hanson JA, Wolfe RA et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000: 57: 307.
3. Heron MP, Hoyert DL, XU J et al. Deaths: Preliminary data for 2006. National Center for Health Statistics. National Vital Statistics Reports, Vol. 56, No 16. June 11, 2008.
4. 2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Table 5.4a, 5.4b, and 5.4c. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI.
5. Matas AJ, Gillingham KJ, Humar A et al. 2202 kidney transplant recipients with 10 years of graft function. Am J Transplant 2008;8:2410.
6. Chobanian AV, Bakris GL, Black HR et al. JNC7. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003: 289: 2560.
7. American Diabetic Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009: 32(Suppl. 1): S13.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of hight blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002: 106: 3143.
9. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction. J Am Coll Cardiol 2004: 44: E1.
10. Antman EM, Hand M, Armstrong PW et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296.
11. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007: 50: e1.
12. Hirsh J, Guyatt G, Albers GW et al. Executive Summary: American College of Chest Physicians evidenced-based clinical practice guidelines (8th Edition). Chest 2008: 6(Suppl): 71s.
13. Kotseva K, Wood D, De Bracker G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009: 16: 121.
14. Gaston RS, Kasiske BL, Fieberg AM et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009: 9: 1811.
15. Holdass H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicenter, randomized, placebo-controlled trial. Lancet 2003: 361: 2024.
16. Holdass H, Fellstrom B, Cole E et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT Extension Study. Am J Transplant 2005: 5: 2929.
17. Groetz W, Siebig S, Olschewski M et al. Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation 2004: 77: 1848.
18. Heinze G, Mitterbauer C, Regele H et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006: 17: 889.
19. Mitterbauer C, Heinze G, Kainz A et al. ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. Nephrol Dial Transplant 2008: 23: 1742.
20. Fellstrom B, Jardine A, Schmieder R et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009: 360: 1395.